Stock Scorecard



Stock Summary for Amarin Corp (AMRN) - $16.21 as of 11/13/2025 3:37:29 PM EST

Total Score

11 out of 30

Safety Score

35 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for AMRN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for AMRN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for AMRN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for AMRN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for AMRN (35 out of 100)

Stock Price Rating (Max of 10) 6
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 7
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for AMRN

RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA ( 1 ) +11.8%, ADJUSTED NET INCOME ( 2 ) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION 11/11/2025 7:27:00 PM
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® ( Icosapent Ethyl ) Reduced Cardiovascular Events in High-Risk Patients 11/9/2025 9:15:00 PM
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® ( Icosapent Ethyl ) Reduced Cardiovascular Events in High-Risk Patients - Amarin Corp ( NASDAQ:AMRN ) 11/9/2025 9:15:00 PM
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid ( EPA ) at American Heart Association ( AHA ) Scientific Sessions 2025 - Amarin Corp ( NASDAQ:AMRN ) 11/3/2025 1:30:00 PM
Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down 10/30/2025 4:08:00 PM
Do Options Traders Know Something About Amarin Stock We Don't? 10/23/2025 2:06:00 PM
Are Medical Stocks Lagging Boston Scientific ( BSX ) This Year? 10/20/2025 1:40:00 PM
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025 - Amarin Corp ( NASDAQ:AMRN ) 10/15/2025 12:00:00 PM
Amarin ( AMRN ) Surges 12.5%: Is This an Indication of Further Gains? 10/6/2025 1:41:00 PM
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick 9/26/2025 1:50:00 PM

Financial Details for AMRN

Company Overview

Ticker AMRN
Company Name Amarin Corp
Country USA
Description Amarin Corporation PLC is a Dublin-based pharmaceutical company dedicated to the development and commercialization of innovative therapies for cardiovascular diseases, primarily within the United States. The company is renowned for its flagship product, Vascepa, which has demonstrated significant efficacy in reducing triglyceride levels in patients at an elevated risk for cardiovascular events. With a robust commitment to enhancing cardiovascular health, Amarin is actively pursuing new clinical applications and market opportunities, thereby solidifying its position as a key player in the healthcare sector.
Sector Name HEALTHCARE
Industry Name DRUG MANUFACTURERS - GENERAL
Most Recent Quarter 9/30/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 16.21
Price 4 Years Ago 67.40
Last Day Price Updated 11/13/2025 3:37:29 PM EST
Last Day Volume 101,783
Average Daily Volume 142,130
52-Week High 20.90
52-Week Low 7.00
Last Price to 52 Week Low 131.57%

Valuation Measures

Trailing PE N/A
Industry PE 28.10
Sector PE 87.16
5-Year Average PE -48.17
Free Cash Flow Ratio 2.74
Industry Free Cash Flow Ratio 29.33
Sector Free Cash Flow Ratio 27.84
Current Ratio Most Recent Quarter 3.45
Total Cash Per Share 5.91
Book Value Per Share Most Recent Quarter 22.06
Price to Book Ratio 0.72
Industry Price to Book Ratio 9.87
Sector Price to Book Ratio 33.38
Price to Sales Ratio Twelve Trailing Months 1.48
Industry Price to Sales Ratio Twelve Trailing Months 4.01
Sector Price to Sales Ratio Twelve Trailing Months 14.03
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics

Total Shares Outstanding 20,792,700
Market Capitalization 337,049,667
Institutional Ownership 17.98%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 2.12%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -94.20%
Annual Earnings Growth -39.03%
Reported EPS 12 Trailing Months -4.20
Reported EPS Past Year -0.83
Reported EPS Prior Year -0.09
Net Income Twelve Trailing Months -86,359,333
Net Income Past Year -82,183,000
Net Income Prior Year -59,112,000
Quarterly Revenue Growth YOY 17.40%
5-Year Revenue Growth -11.86%
Operating Margin Twelve Trailing Months -3.42%

Balance Sheet

Total Cash Most Recent Quarter 122,802,000
Total Cash Past Year 121,038,000
Total Cash Prior Year 199,252,000
Net Cash Position Most Recent Quarter 122,802,000
Net Cash Position Past Year 121,038,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 486,176,000
Total Stockholder Equity Prior Year 552,097,000
Total Stockholder Equity Most Recent Quarter 458,894,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -21,860,000
Free Cash Flow Per Share Twelve Trailing Months -1.05
Free Cash Flow Past Year -31,020,000
Free Cash Flow Prior Year 6,347,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.59
MACD Signal -0.10
20-Day Bollinger Lower Band 13.42
20-Day Bollinger Middle Band 16.38
20-Day Bollinger Upper Band 19.34
Beta 0.72
RSI 37.79
50-Day SMA 12.89
150-Day SMA 17.99
200-Day SMA 23.28

System

Modified 11/12/2025 5:13:39 PM EST